Advanced Accelerator Applications

This page shows the latest Advanced Accelerator Applications news and features for those working in and with pharma, biotech and healthcare.

Novartis buys cancer specialist Endocyte for $2.1bn

177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, acquired along with French company Advanced Accelerator Applications for $3.9bn a year ago.

Latest news

Novartis follows Pfizer and freezes US prices this year

ploughing the cash back into the pipeline-enriching acquisitions of gene therapy company AveXis and radiopharma specialist Advanced Accelerator Applications – and going ahead with the spin-off its Alcon eyecare unit.
AAA board presses go on $3.9bn Novartis takeover

Novartis has started its cash tender offer for French firm Advanced Accelerator Applications, which specialises in radiopharmaceuticals to treat cancer.
Novartis to buy French radiopharma specialist AAA for $3.9bn

Novartis has agreed a $3.9bn deal to buy Advanced Accelerator Applications, a French company specialising in nuclear medicines used to treat tumours. ... The transaction gives Novartis “both near-term product launches as well as a new technology
AAA’s orphan drug Lutathera wins EU green light

Advanced Accelerator Applications’ (AAA) Lutathera (lutetium oxodotreotide) has received European approval to treat adults with unresectable or metastatic, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.
CHMP backs three immuno-oncology drugs for solid tumours

Advanced Accelerator Applications secured a recommendation for Lutathera (lutetium [177Lu] oxodotreotide) - for the treatment of gastro-entero-pancreatic neuroendocrine tumours - and Ipsen got the nod for Xermelo (telotristat ethyl) as a

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest appointments

Abeona Therapeutics appoints new additions to board of directors

Buono was previously the chief executive officer and president of Advanced Accelerator Applications, an international radiopharmaceutical company he founded in 2002.
Former Roche development head joins Asana advisory board

The founder of KAPital Consulting, Dr Dhingra currently serves on the boards of Exosome Diagnostics as chairman of the board, Advanced Accelerator Applications, Five Prime and Autolus.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Director - Digital: Great salary and benefits

Associate Medical Director: Highly Competitive

Director Healthcare PR Communications: Salary TBC

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Editorial Director – Medical Education: Neg

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Director: Negotiable

Account Director – Global Healthcare PR: Salary TBC

Scientific Team Lead: Competitive Salary

Senior Account Executive – Medical Communications: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Scientific Director: Highly Competitive Salary &Benefits

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Account Manager, Healthcare Advertising: Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Director – Head of Public Affairs: Neg

Associate Medical Director: Salary TBC

Project / Account Manager (Medical Education): Salary TBC

Experienced Editor, London, Medical Communications: Competitive package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer (Remote Working): Competitive Salary Offered

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Subscribe to our email news alerts

PMHub

Add my company

Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...